Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

With approval of Merck’s V920 still months away, J&J’s Ebola vaccine finds elevated role in DRC outbreak

Following the recent news that Congolese Health Minister Oly Ilunga Kalenga is pushing for licensure and exclusive use of Merck’s Ebola vaccine in the current DRC outbreak, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his perspective: “Successful delivery of vaccines to an outbreak depends on local capacity, transmission […]
Read more

Added funding provides boost for Vedanta’s experimental microbiome drug

Following the news that microbiome therapeutics developer Vedanta has completed an extended $45.5m series C round, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “The additional funding that Vedanta secured for its series C round will support the company through Phase II clinical development of its microbiome-targeted […]
Read more

Global surgical adhesion barriers market to reach $1.4bn by 2028

The global surgical adhesion barriers market is expected to grow at a compound annual growth rate (CAGR) of 3% to reach $1.4bn by 2028, according to GlobalData, a leading data and analytics company. The company’s latest report: ‘Surgical adhesion barriers – Wound Care Market Analysis and Forecast Model’ reveals that Asia-Pacific will be one of […]
Read more

After Phase III data, Novavax’s ResVax approval for RSV remains uncertain

Following the release of additional Phase III clinical trial (Prepare) data of Novavax’s ResVax, presented at the World Vaccine Congress in Washington, D.C., Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, discusses what the results mean for Novavax’s maternal RSV vaccine: “Despite the stated commitment from Novavax to continue commercialization efforts […]
Read more

Zogenix’s Fintepla projected to reach $872m by 2026 despite recent setback

The FDA recently rejected a marketing application for Zogenix’s Fintepla, an anti-epileptic drug candidate for Dravet syndrome. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, discusses the revelation: “The impact of this setback is not necessarily catastrophic. Fintepla is still at the pre-registration stage in the EU and in […]
Read more

Louisiana achieves major discount from Gilead’s subsidiary through Hepatitis C procurement model

Louisiana’s Department of Health recently announced that Gilead’s subsidiary Asegua Therapeutics has been selected as the pharmaceutical company for hepatitis C procurement model. Arafa Salam, PhD, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the cost savings realized by this innovative procurement strategy: “The strong competition for patient share […]
Read more

UCB’s Cimzia US approval for nr-axSpA places company ahead of competitive biologic space

The approval of UCB’s Cimzia marks the first anti-tumor necrosis factor biologic therapy for non-radiographic axial spondyloarthritis (nr-axSpA) patients in the US, having been already approved for the condition in Europe. Antoine Grey, MBiochem, Immunology Analyst at GlobalData, a leading data and analytics company, offers his view: “UCB’s efforts to expand into a patient population […]
Read more

Sleep boosting DNA repair in damaged neurons could significantly impact the treatment of mental illnesses

A recent study conducted at Bar-Ilan University in Israel found that DNA repair in damaged neurons is most efficient during sleep, and treating sleep disorders is a vastly growing area of innovation in the pharmaceutical industry. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, discusses the revelation: “Considering the […]
Read more

The flow diversion stent market is growing at a CAGR of approximately 2%

Estimated to be approximately 15% of the embolization devices market, the flow diversion stent market is growing at a Compound Annual Growth Rate (CAGR) of approximately 2% by 2028, says GlobalData. In February, “Medtronic’s Pipeline Flex flow diversion device” won expanded FDA approval to treat small or medium wide-neck aneurysms, in addition to its existing […]
Read more
1 … 105 106 107 108